Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 572

1.

Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.

2.

Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.

Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2005 Oct;93(3):237-46.

PMID:
16172796
3.

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2007 Sep 3;97(5):659-69. Epub 2007 Aug 14.

4.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.

5.

Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.

Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2004 Dec 1;10(23):7965-71.

6.

Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.

Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr.

Mol Cell Biol. 1997 Jul;17(7):3629-39.

7.

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2006 Feb;95(3):243-55. Epub 2005 Oct 27.

8.

cDNA microarray analysis of inflammatory breast cancer signatures.

Laere SJ, Vermeulen PB, Dirix LY.

Methods Mol Biol. 2009;512:71-98. doi: 10.1007/978-1-60327-530-9_6.

PMID:
19347274
9.

Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.

Bièche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R.

Clin Cancer Res. 2004 Oct 15;10(20):6789-95.

10.

The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer.

Hou MF, Lin SB, Yuan SS, Tsai SM, Wu SH, Ou-Yang F, Hsieh JS, Tsai KB, Huang TJ, Tsai LY.

Clin Chim Acta. 2003 Aug;334(1-2):137-44.

PMID:
12867284
11.

Elevated expression of genes assigned to NF-kappaB and apoptotic pathways in human periodontal ligament fibroblasts following mechanical stretch.

Ritter N, Mussig E, Steinberg T, Kohl A, Komposch G, Tomakidi P.

Cell Tissue Res. 2007 Jun;328(3):537-48. Epub 2007 Mar 6.

PMID:
17340152
12.

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC.

Clin Cancer Res. 2006 Sep 1;12(17):5047-54.

13.

Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.

Courts C, Montesinos-Rongen M, Martin-Subero JI, Brunn A, Siemer D, Zühlke-Jenisch R, Pels H, Jürgens A, Schlegel U, Schmidt-Wolf IG, Schaller C, Reifenberger G, Sabel M, Warnecke-Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M.

J Neuropathol Exp Neurol. 2007 Mar;66(3):230-7.

PMID:
17356384
14.

Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.

Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr.

Oncogene. 2000 Feb 24;19(9):1123-31.

15.

Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR.

Reinholz MM, Iturria SJ, Ingle JN, Roche PC.

Breast Cancer Res Treat. 2002 Jun;74(3):255-69.

PMID:
12206515
16.

NF-kappa B genes have a major role in inflammatory breast cancer.

Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I.

BMC Cancer. 2008 Feb 4;8:41. doi: 10.1186/1471-2407-8-41.

17.

Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Biswas DK, Iglehart JD.

J Cell Physiol. 2006 Dec;209(3):645-52. Review.

PMID:
17001676
18.

Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells.

Deregowski V, Delhalle S, Benoit V, Bours V, Merville MP.

Biochem Pharmacol. 2002 Sep;64(5-6):873-81.

PMID:
12213581
19.

Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.

Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F.

Br J Cancer. 2005 Oct 31;93(9):1019-23.

20.

Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure.

Aravindan N, Natarajan M, Shaw AD.

J Cardiothorac Vasc Anesth. 2006 Apr;20(2):179-86. Epub 2006 Jan 6.

PMID:
16616657

Supplemental Content

Support Center